U.S. Health and Human Services Secretary Robert F. Kennedy Jr. plans to require all new vaccines be tested against a placebo ...

The report – Prevention Pays: The Economic Value of Adult Vaccination – underscores how a nationwide publicly funded vaccination programme for influenza, shingles, and respiratory syncytial virus (RSV ...

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Dyadic International, Inc. ("Dyadic”, "we”, "us”, "our”, or the "Company”) (NASDAQ: DYAI), a biotechnology company specializing in the development of functional recombinant solutions and proprietary ...

Expert doctors in infectious disease and lung health speak to the transmissibility of walking pneumonia and more infection ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

A single dose of the adult RSV vaccine RSVPreF3 OA prevented RSV–lower respiratory tract disease during 3 virus seasons in adults aged 60+.

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

The infant mortality national rate dropped to about 5.5 infant deaths per 1,000 live births in 2024, according to provisional ...

Vermont has the second lowest state fatality rate in the US (147.2 per 100K; Hawaii 112.9/100K). Mississippi (464.7/100K) and ...

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.